Crucial Vote Looms for CureVac Shareholders as BioNTech Acquisition Nears Finish Line

BioNTech’s Quarterly Results Reveal Challenges

The proposed acquisition of CureVac by BioNTech is accelerating toward its final stages. CureVac investors face a pivotal decision on November 25, when they will cast their votes on the $1.25 billion merger agreement. This critical shareholder meeting approaches as recent financial disclosures from the acquiring company introduce fresh considerations for the deal.

BioNTech presented its third-quarter financial results, reporting substantial revenues of approximately €1.5 billion. Despite this significant income, the company registered a net loss of €28.7 million. Part of this deficit stems from resolving contractual disputes with GSK related to a licensing agreement that originally involved CureVac. This financial entanglement highlights the already complex relationship between the two German biotech firms.